This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Capital Berlin, for one, has become a popular city for business relocation and international investments, with companies such as Volkswagen, Pfizer, and SAP having set up innovation labs there. As the capital city of the United States, Washington, D.C., in the San Francisco Bay Area.
The venture capital landscape continues to test the discipline and diligence of investors and startups alike. Like many other asset classes, venture capital continues to be impacted by lingering macroeconomic factors affecting funding and liquidity prospects. Interest rates are high.
The firm has been publicly traded in Shanghai since 2000, and this would be Hengruis first major capital raise in over two decades. The IPO proceeds will go toward new production and research facilities worldwide, as well as expanding and upgrading existing factories in China.
Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices — as well as their intentions to scale their digital health solutions — to the masses in hopes of securing capital.
Heading into the second half of 2024, venture capital investors remain cautious as they acknowledge persistent challenging dynamics in the landscape. While dry powder reserves have reached record highs, investors are wary about deploying capital with certain recent macroeconomic factors still fresh in mind.
Moderna and BioTech, the pharmaceuticals companies behind the Moderna vaccines for the COVID-19 virus, just announced a new treatment this past December that would greatly reduce the chances of death from melanoma — stirring up substantial interest in investors to funnel capital. a potential cure for skin cancer.
Around the world, investors are favoring companies that have proven their profitability and that can demonstrate how they have successfully utilized their capital. Many pharma companies with expiring patents are on the hunt to acquire biotech companies to address gaps in drug pipelines.
The funding round was led by venture capital firm Andreessen Horowitz. in Funding Founded in 2014, venture capital firm Swanlaab Venture Factory says it, “aims to invest in early-stage Spanish startups with B2B business models and clear technological differentiation.” Swanlaab Venture Factory Receives $48.1M
Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices—as well as their intentions to scale their digital health solutions—to the masses in hopes of securing capital.
On the other hand, 2022 and 2023 brought mass layoffs , falling market capitalizations, and a weakening of global tech spending. According to broker research on the AlphaSense platform, Apple’s release of Vision Pro is a pivotal moment that marks the advent of spatial computing and could transform how people see and interact with technology.
He has a wealth of cross-industry experience in accelerating companies’ growth and raising capital, having spent more than fifteen years in SaaS companies as CFO and COO in industries as varied as manufacturing and biotech. Safaii Board Member Matthew is the founder of Arrowroot Capital. He holds B.A.
A lot of the improvements that I talked about on a macro level, capital efficiency, operations improvements are as important internationally as they are in North America.” – Brian T. M&A IPOs to watch in Pharma and Biotech. Capital deployment and business development were a big focus during the call. JOYY Inc. [YY].
As a business executive who has led ventures in areas such as space technology or data security and helped bridge research and industry, Ive seen first-hand how rapidly deep tech is moving from the lab into the heart of business strategy. For example, generative AI went from research milestone to widespread business adoption in barely a year.
Evolve your primary market research across the healthcare sector when you start your free trial with AlphaSense today. What I’m just starting to see is that people are leaving the pharma companies and joining these [AI tools provider] companies.
According to an outlook published by PwC , “large-cap pharma companies are expected to continue pursuing mid-sized biotech companies to fill pipeline gaps in the face of impending patent cliffs. In January, Roche completed the $2.7
These first-hand perspectives are a critical addition to the secondary research that most professionals rely on in their market research, landscaping, and monitoring. Some are equipped with artificial intelligence capabilities that enable you to maximize and streamline your research, while others are more traditional in their approach.
The venture capital sector is poised for a long-awaited return to dealmaking, fund deployment, and exit opportunities in 2025. Data from the National Venture Capital Association (NVCA) illustrates a massive backlog in VC exits. To train these models requires so much capital that only hyperscalers are going to be able to compete today.
Capital Ones Acquisition of Discover Financial: $35.3 The FTC has not yet stated whether it intends to block the deal, but some Capital One customers have brought a class-action lawsuit in an attempt to block the merger. Leading broker research in the AlphaSense platform referred to it as the biggest software deal of 2024.
Founded in 2007, Civic Science is a consumer intelligence research platform that polls millions of Americans each week covering thousands of topics. HubUX is a research operation platform for private panel management, qualitative automation including video audition questions, and surveys. Happy Researching! ??. [00:00:00].
In this blog, we leverage proprietary expert interviews from the AlphaSense market research platform to understand the top trends shaping the healthcare landscape in 2025. Director with a large managed care organization Biotech and Pharma The Trump administration is expected to bring a relaxation of antitrust enforcement. Kennedy Jr.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content